P H Wiernik

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Anticipation in familial chronic lymphocytic leukaemia
    P H Wiernik
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY 10466, USA
    Br J Haematol 113:407-14. 2001
  2. ncbi Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)
    P H Wiernik
    OLM Comprehensive Cancer Center, New York Medical College, Bronx 10466, USA
    Leuk Lymphoma 40:357-63. 2001
  3. ncbi Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas
    P H Wiernik
    Comprehensive Cancer Center at Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    J Clin Gastroenterol 30:357-63. 2000
  4. ncbi Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity
    E Paietta
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York 10466, USA
    Am J Hematol 66:189-96. 2001
  5. ncbi Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
    J A Sparano
    Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    J Clin Oncol 14:3026-35. 1996
  6. ncbi A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes
    E Paietta
    Immunology Laboratory, Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York 10466, USA
    Cytometry B Clin Cytom 59:1-9. 2004
  7. ncbi Therapeutic efficacy of theophylline in chronic lymphocytic leukemia
    D Makower
    Department of Oncology, Montefiore Medical Center Albert Einstein Cancer Center, Bronx, New York 10467, USA
    Med Oncol 16:69-71. 1999
  8. ncbi Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998)
    P H Wiernik
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Leukemia 18:1605-10. 2004
  9. ncbi Metastatic solid-pseudopapillary tumour of the pancreas: clinico-biological correlates and management
    D T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, NY 10466, USA
    Clin Oncol (R Coll Radiol) 17:358-63. 2005
  10. ncbi Steroid-responsive inclusion body myositis associated with endometrial cancer
    D T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, New York 10466, USA
    Clin Exp Rheumatol 23:93-6. 2005

Collaborators

Detail Information

Publications18

  1. ncbi Anticipation in familial chronic lymphocytic leukaemia
    P H Wiernik
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY 10466, USA
    Br J Haematol 113:407-14. 2001
    ..A significant difference was observed between the ages of onset of the child generation and the SEER population (P < 0.00001), but not between the parent generation and the SEER population. Anticipation characterizes familial CLL...
  2. ncbi Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481)
    P H Wiernik
    OLM Comprehensive Cancer Center, New York Medical College, Bronx 10466, USA
    Leuk Lymphoma 40:357-63. 2001
    ..Both are now well known late complications of Hodgkin's disease treatment...
  3. ncbi Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas
    P H Wiernik
    Comprehensive Cancer Center at Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    J Clin Gastroenterol 30:357-63. 2000
    ..g., gene therapy) are nearing full-scale clinical trial. There are reasons to believe that these and other new initiatives may soon significantly improve the medical management of adenocarcinoma of the exocrine pancreas...
  4. ncbi Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity
    E Paietta
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York 10466, USA
    Am J Hematol 66:189-96. 2001
    ..Epstein-Barr virus (EBV) sequences were detected in one T- and both B-lymphoid cases. Our data suggest that CD56 is expressed at a precursor stage common to the T- and the B-cell lineage...
  5. ncbi Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
    J A Sparano
    Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    J Clin Oncol 14:3026-35. 1996
    ....
  6. ncbi A surrogate marker profile for PML/RAR alpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes
    E Paietta
    Immunology Laboratory, Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York 10466, USA
    Cytometry B Clin Cytom 59:1-9. 2004
    ....
  7. ncbi Therapeutic efficacy of theophylline in chronic lymphocytic leukemia
    D Makower
    Department of Oncology, Montefiore Medical Center Albert Einstein Cancer Center, Bronx, New York 10467, USA
    Med Oncol 16:69-71. 1999
    ..We have treated three advanced CLL patients with theophylline, and seen responses in two. The clinical courses of the responders are presented, and the literature concerning theophylline as therapy for CLL is reviewed...
  8. ncbi Phase II study of theophylline in chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E4998)
    P H Wiernik
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Leukemia 18:1605-10. 2004
    ..025). This suggests that in a CLL population treated with theophylline, induction of an apoptotic response to the drug in vitro is prognostic for absence of clinical progression...
  9. ncbi Metastatic solid-pseudopapillary tumour of the pancreas: clinico-biological correlates and management
    D T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, NY 10466, USA
    Clin Oncol (R Coll Radiol) 17:358-63. 2005
    ..However, the indolent clinical progression of solid-pseudopapillary tumours is similar to that of pancreatic neuroendocrine tumour...
  10. ncbi Steroid-responsive inclusion body myositis associated with endometrial cancer
    D T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, New York 10466, USA
    Clin Exp Rheumatol 23:93-6. 2005
    ..The factors that are associated with a response of IBM to steroids are discussed. An atypical, steroid-responsive form of the disease is delineated...
  11. ncbi Chemotherapy-induced scleroderma: a pleiomorphic syndrome
    D T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    Clin Exp Dermatol 30:141-5. 2005
    ..Analysis of all similar case reports defines the particular features and clinical course of this phenomenon...
  12. ncbi Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials
    E Paietta
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Leukemia 17:1544-50. 2003
    ..Although not statistically significant, the observed association between low CD65s expression and decreased CR rate only in patients over the age of 55 is intriguing...
  13. ncbi Systemic lupus erythematosus and B-cell hematologic neoplasm
    Y Xu
    Comprehensive Cancer Center and Department of Medicine, Our Lady of Mercy Medical Center, New York Medical College, Bronx 10466, USA
    Lupus 10:841-50. 2001
    ..Lastly, EBV infection, found to have a high prevalence in SLE patients, may serve as a common etiological factor in both disorders...
  14. ncbi Treatment of human immunodeficiency virus-related lymphoma
    P H Wiernik
    Our Lady of Mercy Comprehensive Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Semin Hematol 38:27-31. 2001
    ..It is hypothesized that more effective reconstitution of the immune system with HAART may facilitate the inversion of these incidences. Future prospective studies will hopefully answer these questions...
  15. ncbi N-Methylformamide in advanced squamous cancer of the uterine cervix: an Eastern Cooperative Oncology Group phase II trial
    L Rajdev
    Albert Einstein Cancer Center, Bronx, NY, USA
    Invest New Drugs 19:233-7. 2001
    ..There were no complete or partial responses. CONCLUSION: In this population, NMF in the dose and schedule employed exhibited no clinical activity...
  16. ncbi Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature
    D T Alexandrescu
    New York Medical College, Our Lady of Mercy Medical Center, Comprehensive Cancer, Bronx, NY 10466, USA
    Clin Exp Dermatol 30:391-4. 2005
    ..The significance of the changes in adhesion molecules, especially CD138 and CD56, relevant to the development of cutaneous plasmacytomas is discussed...
  17. ncbi Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide
    D Unnikrishnan
    Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY 10466, USA
    Blood 97:1514-6. 2001
    ..Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias are known to be resistant to most chemical methods and electrical cardioversion...
  18. ncbi Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy?
    M M Regan
    IBCSG Statistical Center, Dana Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA
    Ann Oncol 19:1231-41. 2008
    ..PERCHE closed with inadequate accrual; TEXT accrued rapidly...